Haleon Q3 Organic Growth Misses at +2.6%; FY Guidance Cut to ~2.5%, Adds £500M Buyback
HLN is trading near its 52-week low of $8.65 (1.2% below the low).
Summary
Haleon posted Q3 organic revenue growth of 2.6%, below expectations, and cut FY2026 organic growth guidance to around 2.5%. It kept high-single digit profit growth and added £500m to its buyback.
Key Events · Earnings and Guidance · HLN
-
Q3 Organic Growth Below Expectations
Q3 organic revenue growth was +2.6% on £2,868m reported revenue, split +2.1% price and +0.5% volume/mix. Soft cold and flu consumption and lower North America orders held it back.
-
FY2026 Guidance Cut to ~2.5%
Full-year organic revenue growth is now expected to be around 2.5%, while adjusted operating profit growth is still guided to high-single digit at constant currency.
-
China Centrum Import Halt
A raw material classification change forced a stop to imports of Centrum OTC-registered products in China until further notice; that business generated c.£75m of revenue in FY2025. The company says it is not a quality or safety issue.
-
Brazil Model Change Costs Q4 Revenue
The go-to-market overhaul in Brazil is being pulled forward into Q4 2026, expected to cost c.£15-20m of net revenue in the quarter.
Analysis · HLN · Industrial Applications And Services
The guidance cut is the fact that matters most here, with the stock already trading near its 52-week low. Haleon's third quarter came in below its own expectations: organic revenue grew 2.6%, with price contributing 2.1 points and volume/mix only 0.5, and management cut full-year organic growth guidance to around 2.5%. Two specific drags are quantified — a raw material classification change that halted imports of Centrum OTC-registered products into China (a business that generated c.£75m of revenue in FY2025) and an accelerated Brazil go-to-market change costing c.£15-20m of Q4 net revenue. Against that, adjusted operating profit is still guided to high-single digit growth at constant currency, and the company allocated a further £500m to buybacks, which supports the share price while growth is soft.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HLN was trading at $8.55 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $43.8B. The 52-week trading range was $8.65 to $11.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.